Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.

Patrikidou Anna,Domont Julien,Chabaud Sylvie, Ray-Coquard Isabelle,Coindre Jean-Michel,Bui-Nguyen Binh,Adenis Antoine,Rios Maria, Bertucci François,Duffaud Florence,Chevreau Christine,Cupissol Didier,Pérol David, Emile Jean-François,Blay Jean-Yves,Le Cesne Axel, Null Null

European Journal of Cancer（2016）

引用 76|浏览27

暂无评分

摘要

•KIT exon 11 mutation is an independent prognostic factor for PFS and OS in GIST patients.•Clinico-biological factors (gender, PS, tumour size, lymphocyte & neutrophil count) are also significant.•Subsets of exon 11 mutations have significantly different response patterns and PFS in GIST patients.

查看译文

关键词

GIST,imatinib mesylate,mutational status,prognostic factors,outcome analysis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要